Keywords: BioMarin, BMRN, ZyStor, Pompe disease, PKU, Kuvan

BioMarin buys ZyStor - and Pompe drug - in staged deal worth a potential $115 million; moves PKU drug into Ph III

Article | 19 August 2010

Print This

In a second acquisition this year, US drugmaker BioMarin Pharmaceutical (Nasdaq: BMRN) says that it has bought ZyStor Therapeutics, a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in